Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYANNASDAQ:OKYOOTCMKTS:OPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYANCyanotech$0.42+2.5%$3.01$2.37▼$6.29$2.99M-0.113,483 shs25,887 shsOKYOOKYO Pharma$1.89+1.1%$1.43$0.81▼$1.98$63.98M-0.38131,543 shs12,042 shsOPTIOptec International$0.00-5.3%$0.00$0.00▼$0.00$21KN/A973,103 shs1.06 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYANCyanotech+0.62%-0.51%-5.25%+19.83%+33.58%OKYOOKYO Pharma+6.86%+6.86%+37.25%+34.53%+30.77%OPTIOptec International-5.26%0.00%0.00%-18.18%+5.88%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYANCyanotechN/AN/AN/AN/AN/AN/AN/AN/AOKYOOKYO Pharma2.5547 of 5 stars3.55.00.00.01.51.70.0OPTIOptec InternationalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYANCyanotech 0.00N/AN/AN/AOKYOOKYO Pharma 3.00Buy$7.00270.17% UpsideOPTIOptec International 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OPTI, CYAN, OKYO, and PHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025OKYOOKYO PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYANCyanotech$23.07M0.13N/AN/A$1.33 per share0.31OKYOOKYO PharmaN/AN/AN/AN/A($0.20) per shareN/AOPTIOptec InternationalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYANCyanotech-$5.27M-$0.66N/A∞N/A-19.50%-44.71%-19.12%N/AOKYOOKYO Pharma-$16.83MN/A0.00N/AN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYANCyanotechN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AOPTIOptec InternationalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYANCyanotech0.111.060.28OKYOOKYO PharmaN/A0.28N/AOPTIOptec InternationalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYANCyanotech24.40%OKYOOKYO Pharma2.97%OPTIOptec InternationalN/AInsider OwnershipCompanyInsider OwnershipCYANCyanotech29.10%OKYOOKYO Pharma40.46%OPTIOptec International50.34%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYANCyanotech957.16 million5.07 millionNot OptionableOKYOOKYO Pharma733.84 million20.15 millionNot OptionableOPTIOptec International111.65 millionN/ANot OptionableOPTI, CYAN, OKYO, and PHE HeadlinesRecent News About These CompaniesOptec International Inc.May 23, 2025 | barrons.comOptec Technology Ltd.April 29, 2025 | optics.orgNew Optec CEO Updates ShareholdersJanuary 16, 2025 | globenewswire.comNew Optec CEO Updates ShareholdersJanuary 16, 2025 | prismmediawire.comGlobal Optical Current Transformer Market Size Forecasted to Surpass USD 353.0 Million Valuation by 2033, Surging at 8.4% CAGRNovember 14, 2024 | fmiblog.comSITC International Expands Fleet with New Vessel OrdersOctober 30, 2024 | markets.businessinsider.comAston University researcher develops new optical technique that could revolutionise medical diagnosticsOctober 25, 2024 | eurekalert.orgbit.bio Wins Landmark Patent Defence for Groundbreaking opti-ox™ Cell Programming TechnologyOctober 16, 2024 | standard-journal.comOptical illusion psychology test: What you see first reveals if you are optimist or too cautious in lifeOctober 4, 2024 | timesofindia.indiatimes.comOpti Digital Welcomes Guillem Fiter as Chief Marketing OfficerSeptember 17, 2024 | exchangewire.comOGP exhibiting exciting lineup of metrology systems at IMTS 2024September 6, 2024 | insights.globalspec.comAndersen Global Enters Japan with the Collaborating Firm OptiAugust 30, 2024 | tmcnet.comThe Optical Women’s Association Announces Global Connection Event at Silmo ParisAugust 29, 2024 | invisionmag.comOptical Communication and Networking Equipment Market to Reach $54.0 Billion, Globally, by 2032 at 8.7% CAGR: Allied Market ResearchAugust 20, 2024 | tmcnet.comEngineers bring efficient optical neural networks into focusAugust 15, 2024 | sciencedaily.comOptical navigation tech could streamline planetary explorationAugust 7, 2024 | msn.comIso-propagation vortices: optical multiplexing for unprecedented information capacityMay 18, 2024 | eurekalert.orgIDTechEx Release New Global Optical & Radio Frequency Metamaterials Market ReportMay 13, 2024 | tmcnet.comGlobal Optical Coherence Tomography IndustryMay 6, 2024 | fmiblog.comZeroTech Optics Appoints Lead for International SalesMay 3, 2024 | sgbonline.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock Lyft: Profitability Milestone and Buyback Fuel Investor OptimismBy Jeffrey Neal Johnson | May 13, 2025View Lyft: Profitability Milestone and Buyback Fuel Investor OptimismOPTI, CYAN, OKYO, and PHE Company DescriptionsCyanotech NASDAQ:CYANCyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.OKYO Pharma NASDAQ:OKYO$1.89 +0.02 (+1.12%) As of 10:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Optec International OTCMKTS:OPTI$0.0018 0.00 (-5.26%) As of 06/3/2025 02:45 PM EasternOptec International, Inc. engages in selling and marketing optimized fuel maximizer units in North America and internationally. It markets optimized fuel maximizer for passenger vehicles, intermediate/medium duty trucks, off-road equipment, generator systems, heavy duty diesel on-road vehicles, and transportation refrigeration units. The company was formerly known as Green Meadow Products, Inc. and changed its name to Optec International, Inc. in August 2017. Optec International, Inc. was founded in 2012 and is based in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Tesla’s Lofty 200 P/E Could Mean More Upside Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
